Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Selected Thoughts on Hydrophobicity in Drug Design.

Literature DB >> 33562230

Selected Thoughts on Hydrophobicity in Drug Design.

Abstract

The fundamental aim of drug design in research and development is to invent molecules with selective affinity towards desired disease-associated targets. At the atomic loci of binding surfaces, systematic structural variations can define affinities between drug candidates and biomolecules, and thereby guide the optimization of safety, efficacy and pharmacologic properties. Hydrophobic interaction between biomolecules and drugs is integral to binding affinity and specificity. Examples of antiviral drug discovery are discussed.

Entities: CellLine Chemical Disease Gene Species

Keywords: acyclic nucleoside phosphonates; drug design; hydrophobic interaction; nucleotide antivirals

Mesh：

Substances：

Year: 2021 PMID： 33562230 PMCID： PMC7914489 DOI： 10.3390/molecules26040875

Source DB: PubMed Journal: Molecules ISSN： 1420-3049 Impact factor: 4.411

24 in total

Review 1. Profound methyl effects in drug discovery and a call for new C-H methylation reactions.

Authors: Heike Schönherr; Tim Cernak
Journal: Angew Chem Int Ed Engl Date: 2013-10-22 Impact factor: 15.336

2. Improvement of bone mineral density and markers of proximal renal tubular function in chronic hepatitis B patients switched from tenofovir disoproxil fumarate to tenofovir alafenamide.

Authors: Tse-Ling Fong; Brian T Lee; Andy Tien; Mimi Chang; Carolina Lim; Aiden Ahn; Ho S Bae
Journal: J Viral Hepat Date: 2019-01-16 Impact factor: 3.728

3. A novel selective broad-spectrum anti-DNA virus agent.

Authors: E De Clercq; A Holý; I Rosenberg; T Sakuma; J Balzarini; P C Maudgal
Journal: Nature Date: 1986 Oct 2-8 Impact factor: 49.962

4. Twenty-eight day safety, antiviral activity, and pharmacokinetics of tenofovir alafenamide for treatment of chronic hepatitis B infection.

Authors: Kosh Agarwal; Scott K Fung; Tuan T Nguyen; Wendy Cheng; Eric Sicard; Stephen D Ryder; John F Flaherty; Eileen Lawson; Sally Zhao; G Mani Subramanian; John G McHutchison; Edward J Gane; Graham R Foster
Journal: J Hepatol Date: 2014-10-30 Impact factor: 25.083

5. Synthesis and antiherpes virus activity of phosphate and phosphonate derivatives of 9-[(1,3-dihydroxy-2-propoxy)methyl]guanine.

Authors: E J Prisbe; J C Martin; D P McGee; M F Barker; D F Smee; A E Duke; T R Matthews; J P Verheyden
Journal: J Med Chem Date: 1986-05 Impact factor: 7.446

6. Selective intracellular activation of a novel prodrug of the human immunodeficiency virus reverse transcriptase inhibitor tenofovir leads to preferential distribution and accumulation in lymphatic tissue.

Authors: William A Lee; Gong-Xin He; Eugene Eisenberg; Tomas Cihlar; Swami Swaminathan; Andrew Mulato; Kenneth C Cundy
Journal: Antimicrob Agents Chemother Date: 2005-05 Impact factor: 5.191

7. Antisense gene inhibition by oligonucleotides containing C-5 propyne pyrimidines.

Authors: R W Wagner; M D Matteucci; J G Lewis; A J Gutierrez; C Moulds; B C Froehler
Journal: Science Date: 1993-06-04 Impact factor: 47.728

8. Influenza neuraminidase inhibitors possessing a novel hydrophobic interaction in the enzyme active site: design, synthesis, and structural analysis of carbocyclic sialic acid analogues with potent anti-influenza activity.

Authors: C U Kim; W Lew; M A Williams; H Liu; L Zhang; S Swaminathan; N Bischofberger; M S Chen; D B Mendel; C Y Tai; W G Laver; R C Stevens
Journal: J Am Chem Soc Date: 1997-01-29 Impact factor: 15.419

Review 2. Tribute to John C. Martin at the Twentieth Anniversary of the Breakthrough of Tenofovir in the Treatment of HIV Infections.

Authors: Erik De Clercq
Journal: Viruses Date: 2021-12-02 Impact factor: 5.048

2 in total